Seeking Alpha

Pernix Therapeutics (PTX -2.6%) slips this morning, despite its announcement that its Hawthorn...

Pernix Therapeutics (PTX -2.6%) slips this morning, despite its announcement that its Hawthorn Pharmaceuticals unit has received FDA approval for Vituz, a prescription medication for coughs and colds. The company also said its Cypress Pharmaceuticals unit got final FDA approval for Mefenamic Acid Capsules, a generic version of Ponstel, for relief of mild-to-moderate pain in patients 14 years of age and older and the treatment of primary dysmenorrhea.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs